Multiple myeloma trials in United States

In United States 297 Also abroad 703

297 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Horizon Two: HR NDMM (MMRC-100)
Where
Atlanta, Boston, Chapel Hill, Charlotte, Chicago, Detroit, Duarte, Nashville, New York, Rochester, St Louis
Age
18 years and over
People
300
Run by
Multiple Myeloma Research Consortium
See details and how to joinNCT07053436
No phaseTaking people
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Where
Albert Lea, Eau Claire, Jacksonville, La Crosse, Mankato, Rochester, Scottsdale
Age
18 years and over
People
82
Run by
Mayo Clinic
See details and how to joinNCT06630104
Phase 2Taking people
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, Uniondale
Age
60 years and over
People
215
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT06679829
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Columbus, Fort Wayne, St. Petersburg, Tacoma, Westbrook
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
No phaseTaking people
Rutgers University Study of the Genetics of Blood Cancers
Where
Piscataway
Age
18 years to 110 years
People
10,000
Run by
Rutgers, The State University of New Jersey
See details and how to joinNCT07714044
Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Where
Bethesda, Bullhead City, Canton, Greenville, Huntington Park, Morrisville, Rockville, St. Petersburg, Wilson
Age
18 years and over
People
386 worldwide
Run by
Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00
Phase 2Taking people
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Where
Jacksonville
Age
18 years and over
People
27
Run by
Mayo Clinic
See details and how to joinNCT07285044
No phaseTaking people
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Where
Rochester
Age
18 years and over
People
150
Run by
Mayo Clinic
See details and how to joinNCT07850284
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Albany, Atlanta, Austin, Boston, Chapel Hill, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Coral Gables, Dallas, Denver, Detroit, Gainesville, Gilbert, Houston, Iowa City, Kansas City, La Jolla, Louisville, Madison, Milwaukee, Nashville, New Haven, New York, Park Ridge, Phoenix, Portland, Puyallup, Richmond, Rochester, Sacramento, Salt Lake City, Santa Monica, Seattle, Tampa, The Bronx, Tucson, Washington D.C., Winston-Salem
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 2Taking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Cleveland, Denver, Durham, New Haven, New York, Richmond, Rochester, San Francisco, Seattle
Age
18 years and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00
Phase 1Taking people
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Where
Atlanta, Denver
Age
18 years and over
People
276 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00
Phase 1Taking people
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Where
Atlanta, Charlottesville, Dallas, Denver, Duarte, Houston, Iowa City, Nashville, New York, Phoenix, Rochester, St Louis, Tampa
Age
18 years and over
People
40
Run by
AstraZeneca
See details and how to joinNCT07073547
Phase 1/2Taking people
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Where
Atlanta, Duarte, Houston, Irvine, New York, Scottsdale
Age
18 years and over
People
360
Run by
Fortvita Biologics (USA)Inc.
See details and how to joinNCT07336472
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Albany, Atlanta, Baltimore, Beverly Hills, Birmingham, Boston, Canton, Chicago, Cincinnati, Dallas, Dayton, Denver, Detroit, Durham, East Brunswick, Eugene, Farmington, Greenville, Indianapolis, Iowa City, Irvine, Jacksonville, Los Angeles, Louisville, Lubbock, Mineola, Minneapolis, Nashville, New York, Omaha, Orange, Pembroke Pines, Phoenix, Rochester, Salt Lake City, Santa Fe, Shirley, Shreveport, Springdale, Tacoma, Waukee
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 1Taking people
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Where
Covington, Dyer, Everett, Houston, Jacksonville, Margate, Ocala, Olympia, Plantation, Springdale, Tamarac
Age
18 years and over
People
258 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07477587
Phase 2Taking people
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Where
Boston, Chicago
Age
18 years and over
People
83
Run by
University of Chicago
See details and how to joinNCT05789303
No phaseTaking people
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Where
Portland
Age
18 years and over
People
45
Run by
OHSU Knight Cancer Institute
See details and how to joinNCT06784167
Phase 1/2Taking people
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Where
Atlanta, Birmingham, Boston, Charlotte, Milwaukee, Nashville, New York, Philadelphia, San Francisco
Age
18 years and over
People
190
Run by
ModernaTX, Inc.
See details and how to joinNCT07116616
Phase 2Taking people
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Where
Albuquerque, Allentown, Altamonte Springs, Ann Arbor, Atlanta, Auburn, Augusta, Aventura, Belfast, Berkeley, Bethlehem, Biddeford, Birmingham, Bismarck, Bluffton, Bonita Springs, Bonney Lake, Bradenton, Brandon, Brewer, Bridgeport, Brunswick, Burlington, Cape Coral, Cedar City, Chapel Hill, Charlotte, Chicago, Cincinnati, Clearwater, Concord, Coral Gables, Deerfield Beach, Detroit, East Stroudsburg, ‘Ewa Beach, Fairfax, Fargo, Federal Way, Flint, Fort Lauderdale, Fort Myers, Gainesville, Germantown, Gig Harbor, Grafton, Grand Rapids, Green Bay, Hartford, Hazleton, Hilton Head Island, Honolulu, Houston, Indianapolis, Kennebunk, Kenosha, Kettering, Kittery, Lake Success, Lansing, Largo, Las Cruces, Lecanto, Livonia, Los Angeles, Manchester, Marinette, Meriden, Miami, Milwaukee, Mount Kisco, Naples, Nashville, New Britain, New Hyde Park, New York, Norway, Norwich, Oakland, Ocala, Olympia, Omaha, Orange City, Orlando, Oshkosh, Palo Alto, Philadelphia, Phoenix, Plantation, Pontiac, Port Charlotte, Portland, Portsmouth, Puyallup, Racine, Rego Park, Rio Rancho, Rockport, Roseville, Sacramento, Saginaw, Salt Lake City, Sanford, San Francisco, San Jose, San Leandro, Santa Barbara, Santa Clara, Santa Cruz, Sarasota, Savannah, Scarborough, Seattle, Sheboygan, Sioux Falls, Sleepy Hollow, South Portland, St. George, St. Petersburg, Summit, Sunnyvale, Tacoma, Tampa, Tavares, The Villages, Topsham, Torrington, Traverse City, Trinity, Two Rivers, Vallejo, Venice, Walnut Creek, Warren, Wauwatosa, Wells, West Chester, Willimantic, Winter Park, York Village
Age
12 years and over
People
4,200 worldwide
Run by
American Society of Clinical Oncology
See details and how to joinNCT02693535
Phase 2Enrolling by invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Where
Austin, Miami, St Louis
Age
1 year and over
People
500 worldwide
Run by
Autolus Limited
See details and how to joinNCT03628612
Phase 1Taking people
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Where
Hackensack
Age
18 years and over
People
18
Run by
Hackensack Meridian Health
See details and how to joinNCT03909412
Phase 2Taking people
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Where
Hackensack, Washington D.C.
Age
18 years and over
People
96
Run by
Hackensack Meridian Health
See details and how to joinNCT04661137
Phase 2Taking people
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Where
Miami
Age
18 years and over
People
104
Run by
University of Miami
See details and how to joinNCT06997081
Phase 2Taking people
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Where
Ann Arbor, Atlanta, Bethesda, Boston, Charlotte, Chicago, Cleveland, Hackensack, Iowa City, Jacksonville, Milwaukee, New Brunswick, Omaha, Philadelphia, Phoenix, Rochester, San Francisco, Seattle, St Louis, Tampa, Winston-Salem
Age
18 years and over
People
100 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT07096778
Phase 1Taking people
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
Where
Rochester
Age
18 years and over
People
40
Run by
Vyriad, Inc.
See details and how to joinNCT07802717